Experts in preclinical and clinical ECG safety assessment discuss how advances in arrhythmia detection and concentration effects modelling improve study outcomes.

Comprehensive assessment of ECG intervals and arrhythmias is now practical in both preclinical and clinical research studies. A subset of the available information is currently required by the FDA, and researchers are challenged to balance the value of knowing more against potential liabilities of evaluating and submitting incremental data.

During this webinar, sponsored by VivaQuant, experts review advances in ECG safety assessment including reductions in interval measurement variability, reductions in confidence limits in concentration effect models and accurate reporting of up to 20 common arrhythmias.

The clinical perspective is delivered by Dr. Jay W. Mason. He discusses reductions in interval measurement variability and confidence limits in concentration effect models and review the implications for clinical TQT studies and Phase I (IQ-CSRC) studies supporting TQT waivers, stressing why tighter confidence limits and more accurate measurements matter.

Following, Mike Gralinski, CEO of CorDynamics, offers a preclinical perspective on the potential of incorporating detailed assessment of arrhythmias for every cardiovascular study, and shares his thoughts on how and when this additional information should be leveraged. He discusses the value of knowledge versus liability of disclosure, the potential value of pre-study arrhythmia screening and incorporating baseline/control arrhythmia assessment.

Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.

Resources

To download a PDF copy of the presentation, click on the “LinkedIn SlideShare” icon located in the bottom-right corner of the slide-viewer. From the SlideShare landing page click the “Download” button to retrieve the file.

Presenters


University of Utah

CEO and Co-Founder
CorDynamics

Production Partner

VivaQuant LLC

VivaQuant provides products, services, and technology that yield more accurate and useful information from ECG and other vital signs.

Additional Content From VivaQuant LLC

Related Content

Fishing for Insights from Single-Lead and Multi-Lead ECG of Live Adult Zebrafish

Fishing for Insights from Single-Lead and Multi-Lead ECG of Live Adult Zebrafish

In this webinar, Dr. Thao Nguyen discusses the exciting discoveries that her research team has made, debunks some common myths, and shares best-practices for data acquisition, analysis, and interpretation. Her in vivo studies of adult zebrafish cardiac electrophysiology rely on single-lead and multi-lead surface ECG in live anesthetized adult zebrafish.
Myeloid Cells and Cardiovascular Health

Myeloid Cells and Cardiovascular Health

Dr. Matthias Nahrendorf discusses current concepts of cell supply by the hematopoietic system, highlights open questions, and describes imaging tools for studying monocytes, macrophages and their progenitors.